Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) announced National Medical Products Administration (NMPA) marketing approval for Intrarosa Pessary, licensed from U.S.-based Cosette Pharmaceuticals. The prasterone (DHEA)-containing steroid becomes the only estrogen-free therapy approved in China for daily topical treatment of moderate to severe vulvar and vaginal atrophy in postmenopausal women (excluding urinary symptoms), addressing an underserved menopausal health market with ~60 million affected women in China.
Regulatory Milestone
Item
Detail
Agency
NMPA (China)
Approval Type
Marketing authorization (imported drug)
Product
Intrarosa Pessary (prasterone 6.5mg)
Licensor
Cosette Pharmaceuticals (U.S.)
Licensee
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950)
Indication
Moderate to severe vulvar and vaginal atrophy in postmenopausal women (excluding urinary symptoms)
Global Approvals
FDA and EMA approved – only estrogen-free steroid for daily topical use in menopausal dyspareunia
Dyspareunia (pain during intercourse) – key patient-reported outcome
Market Context & Commercial Strategy
Factor
Implication
China Menopausal Women
~60 million postmenopausal women; 30–50% experience vulvovaginal atrophy; <10% receive adequate treatment – massive unmet need
Current Standard of Care
Estrogen creams/tablets (premarin, estradiol) – effective but systemic absorption concerns, endometrial monitoring required, breast cancer risk stigma
Intrarosa Differentiation
Estrogen-free = no endometrial stimulation, no black-box warning, breast cancer survivor eligible – addresses key patient/physician barriers
Lee’s Pharma Positioning
Women’s health franchise expansion beyond existing gynecology portfolio; first-mover advantage in DHEA category
Pricing Strategy
Expected RMB 8,000–12,000 annual therapy cost – premium to generic estrogen but justified by safety profile and convenience
Commercial Timeline: Launch Q2 2026; targeting tertiary hospital gynecology departments and menopause specialty clinics; e-commerce channel for patient awareness and adherence
Revenue Potential: Peak China sales RMB 300–500 million annually assuming 5–8% penetration of addressable postmenopausal atrophy market
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch execution, physician education, and market penetration for Intrarosa in China. Actual results may differ due to cultural sensitivities around menopausal sexual health, competitive dynamics with established estrogen therapies, and reimbursement negotiations for menopausal symptom management.-Fineline Info & Tech
By Fineline Cube